Drug eluting implantable medical device
A drug eluting medical device is provided for implanting into vessels or luminal structures within the body of a patient. The coated medical device, such as a stent, vascular, or synthetic graft comprises a coating consisting of a controlled-release matrix of a bioabsorbable, biocompatible, bioerodible, biodegradable, nontoxic material, such as a Poly(DL-Lactide-co-Glycolide) polymer, and at least one pharmaceutical substance, or bioactive agent incorporated within the matrix or layered within layers of matrix. In particular, the drug eluting medical device when implanted into a patient, delivers the drugs or bioactive agents within the matrix to adjacent tissues in a controlled and desired rate depending on the drug and site of implantation.
1 . A medical device comprising a coating for controlled release of one or more pharmaceutical substances to adjacent tissue for inhibiting restenosis, wherein the coating comprises a bioabsorbable matrix, one or more pharmaceutical substances and a nonabsorbable polymer selected from ethylene vinyl acetate and methylmethacrylate.
2 . The medical device of claim 1 , wherein the device is structured and configured to be implanted in a patient, and wherein at least one surface of the device comprises one or more base materials.
3 . The medical device of claim 1 , wherein the medical device is a stent, a vascular or other synthetic graft, or a stent in combination with a synthetic graft.
4 . The medical device of claim 1 , wherein the medical device is a vascular stent.
5 . The medical device of claim 2 , wherein the one or more base materials is/are biocompatible.
6 . The medical device of claim 2 , wherein the one or more base materials is/are selected from the group consisting of stainless steel, Nitinol, MP35N, gold, tantalum, platinum, platinum iridium, carbon fiber, cellulose acetate, cellulose nitrate, silicone, cross-linked polyvinyl acetate (PVA) hydrogel, cross-linked PVA hydrogel foam, polyurethane, polyamide, styrene isobutylene-styrene block copolymer (Kraton), polyethylene terephthalate, polyester, polyorthoester, polyether sulfone, polycarbonate, polypropylene, high molecular weight polyethylene, polytetrafluoroethylene, polyesters of polylactic acid, polyglycolic acid, copolymers thereof, a polyanhydride, polycaprolactone, polyhydroxybutyrate valerate, extracellular matrix components, proteins, collagen, fibrin, and mixtures thereof.
7 . The medical device of claim 1 , wherein the bioabsorbable matrix comprises one or more polymers or oligomers which is/are selected from the group consisting of poly(lactide-co-glycolide), polylactic acid, polyglycolic acid, a polyanhydride, polycaprolactone, polyhydroxybutyrate valerate, and mixtures or copolymers thereof.
8 . The medical device of claim 1 , wherein the coating comprises poly(DL-lactide-co-glycolide).
9 . The medical device of claim 7 , wherein the bio-absorbable matrix comprises poly(DL-lactide).
10 . The medical device of claim 1 , wherein the one or more pharmaceutical substances is/are selected from the group consisting of antibiotics/antimicrobials, antiproliferatives, antineoplastics, antioxidants, endothelial cell growth factors, thrombin inhibitors, immunosuppressants, anti-platelet aggregation agents, collagen synthesis inhibitors, therapeutic antibodies, nitric oxide donors, wound-healing agents, therapeutic gene transfer constructs, extracellular matrix components, vasodilators, thrombolytics, anti-metabolites, growth factor agonists, antimitotics, steroidal and nonsteroidal antiinflammatory agents, angiotensin converting enzyme (ACE) inhibitors, free radical scavengers, and anti-cancer chemotherapeutic agents.
11 . The medical device of claim 10 , wherein the one or more pharmaceutical substances is/are selected from the group consisting of paclitaxel, cyclosporin A, mycophenolic acid, mycophenolate mofetil acid, rapamycin, azathioprene, tacrolimus, tranilast, dexamethasone, another corticosteroid, everolimus, retinoic acid, vitamin E, a statin, and probucol.
12 . The medical device of claim 11 , wherein the one or more pharmaceutical substances is/are cyclosporin A and/or mycophenolic acid.
13 . The medical device of claim 11 , wherein the one or more pharmaceutical substances is/are mycophenolic acid and/or vitamin E.
14 . The medical device of claim 8 , wherein the poly(DL-lactide-co-glycolide) comprises from about 50 to 99% of the polymer in the coating.
15 . The medical device of claim 8 , wherein the poly(DL-lactide-co-glycolide) polymer comprises from about 50 to 85% lactide polymer and from about 15 to 50% glycolide polymer.
16 . The medical device of claim 1 , wherein the pharmaceutical substance comprises from about 1 to about 50% (w/w) of the composition
17 . The medical device of claim 11 , wherein the one or more pharmaceutical substances is/are paclitaxel and/or cyclosporin A.
18 . (canceled)
19 . (canceled)
20 . The medical device of claim 1 , wherein the ethylene vinyl acetate is ethylene vinyl acetate 25.
21 . The medical device of claim 1 , wherein the coating comprises a single homogeneous layer comprising poly(DL-lactide-co-glycolide) and the pharmaceutical substances.
22 . The medical device of claim 1 , wherein the coating comprises multiple layers of the poly(DL-lactide-co-glycolide) polymer and the pharmaceutical substances.
23 . The medical device of claim 1 , wherein the coating comprises multiple layers of the pharmaceutical substances and multiple layers of poly(DL-lactide-co-glycolide) polymer.
24 . (canceled)
25 . (canceled)
26 . A method of treating vascular disease, comprising implanting the medical device of any one of claims 1 - 17 and 20 - 23 into a patient in need of such treatment.
27 . The medical device of claim 2 , wherein the ethylene vinyl acetate is ethylene vinyl acetate 25.
28 . A method of treating vascular disease, comprising implanting the medical device of claim 27 into a patient in need of such treatment.